Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Both Alzheimer's disease and senile dementia of the Alzheimer type (AD/SDAT) are progressive dementias characterized neuropathologically by the presence in the cerebral cortex of numerous neurofibrillary tangles and neuritic plaques. We use the abbreviation AD/SDAT to denote all such cases, irrespective of age of onset. Studies of neurotransmitter-related parameters in autopsied brain tissues from patients with AD/SDAT have, to date, been confined to five putative transmitter systems. Acetycholine-releasing neurones seem to be most markedly and consistently affected, as judged by the extensive reductions in choline acetyltransferase (ChAT) and acetylcholinesterase activities that have been reported. Despite numerous studies, there is no consistent evidence for the involvement of neurones releasing dopamine, noradrenaline, serotonin, or gamma-aminobutyric acid in AD/SDAT, nor for loss of muscarinic cholinergic receptors. Thus, the involvement of cholinergic neurones in AD/SDAT seems to be specific. However, the possible involvement of neurones using other chemicals as transmitters has yet to be explored. The recent recognition of the existence of so-called 'peptidergic neurones' in the mammalian brain (for review see ref. 8) and the availability of radioimmunoassay (RIA) techniques for studying these peptides, have led us to begin a systematic investigation of neuropeptides in autopsied brain tissue from cases of AD/SDAT, and from neurologically normal individuals. We report here results obtained with a RIA for somatostatin, showing that somatostatin-like immunoreactivity in the cerebral cortex is reduced in tissue from AD/SDAT patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aβ not only affects intracellular vesicular trafficking but could also affect primary cilia function directly or indirectly via its cognate binding receptors such as LRP1 [15, 50, 75].”
From Abnormal accumulation of extracellular vesicles in hippocampal dystrophic axons and regulation by the primary cilia in Alzheimer's disease (2023) · cites this paper as [15]
In the citing paper
“In addition, SST administration has been shown to be effective in improving cognitive impairment in AD patients [12, 15].”
From Abnormal accumulation of extracellular vesicles in hippocampal dystrophic axons and regulation by the primary cilia in Alzheimer's disease (2023) · cites this paper as [15]
In the citing paper
“Dysfunctional SOMs have been identified as a hallmark of AD, and loss of SOMs in the cortex is associated with AD pathologies [10, 15, 65].”
From Abnormal accumulation of extracellular vesicles in hippocampal dystrophic axons and regulation by the primary cilia in Alzheimer's disease (2023) · cites this paper as [15]
In the citing paper
“Additionally, AD patients have a specific loss of somatostatin-positive interneurons in the cortex [94] and hippocampus [95].”
From Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease (2019) · cites this paper as [94]
Citations
Cites
Hökfelt, T., Johansson, O., Ljungdahl, Å., Lundberg, J. M., & Schultzberg, M. (1980) · Nature · doi:10.1038/284515a0 · Cited by 1,547
NECROPSY EVIDENCE OF CENTRAL CHOLINERGIC DEFICITS IN SENILE DEMENTIA
Perry, E., Perry, R., Blessed, G., & Tomlinson, B. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91780-9 · Cited by 1,069
Neurotransmitter-related enzymes in senile dementia of the alzheimer type
Davies, P. (1979) · Brain Research · doi:10.1016/0006-8993(79)90336-6 · Cited by 634
Self-citationThe Prevalence and Malignancy of Alzheimer Disease: A Major Killer
Katzman, R. (1976) · Archives of Neurology · doi:10.1001/archneur.1976.00500040001001 · Cited by 619
Self-citationDementia of the Alzheimer Type
Terry, R. D., & Davies, P. (1980) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.03.030180.000453 · Cited by 529
Self-citationPrevalence and Malignancy of Alzheimer Disease
Lijtmaer, H., Fuld, P. A., & Katzman, R. (1976) · Archives of Neurology · doi:10.1001/archneur.1976.00500040088017 · Cited by 517
Self-citationNEOCORTICAL CHOLINERGIC NEURONS IN ELDERLY PEOPLE
White, P., Goodhardt, M. J., Keet, J. P., Hiley, C. R., Carrasco, L. H., Williams, I. E. I., & Bowen, D. M. (1977) · The Lancet · doi:10.1016/s0140-6736(77)92114-6 · Cited by 489
Davies, P., & Verth, A. H. (1977) · Brain Research · doi:10.1016/0006-8993(77)90758-2 · Cited by 313
Self-citationRadioimmunoassay for GH-Release Inhibiting Hormone
Arimura, A., Sato, H., Coy, D. H., & Schally, A. V. (1975) · Experimental Biology and Medicine · doi:10.3181/00379727-148-38631 · Cited by 302
Research works printed but not linked: 1
- Wisniewski, H. M. & Terry, R. D. in Neurobiology of Aging (eds Terry, R. D. & Gershon, S.) 265–280 (Raven, New York, 1976).
Cited by
Items 101–200 of 889
A tool kit of highly selective and sensitive genetically encoded neuropeptide sensors
Wang, H., Qian, T., Zhao, Y., Zhuo, Y., Wu, C., Osakada, T., Chen, P., Chen, Z., Ren, H., Yan, Y., et al. (2023) · Science · doi:10.1126/science.abq8173 · Cited by 153
Somatostatin Inhibits Excitatory Transmission at Rat Hippocampal Synapses via Presynaptic Receptors
Boehm, S., & Betz, H. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-11-04066.1997 · Cited by 163
“In addition, levels of somatostatin are altered in several human brain dysfunctions, such as senile dementia of the Alzheimer type (Davies et al., 1980) and temporal lobe epilepsy (Robbins et al., 1991).”
BackgroundBissette, G. (1985) · JAMA · doi:10.1001/jama.254.21.3067 · Cited by 165
Nicol Ferrier, I., Roberts, G. W., Crow, T. J., Johnstone, E. C., Owens, D. G. C., Lee, Y. C., O'Shaughnessy, D., Adrian, T. E., Polak, J. M., & Bloom, S. R. (1983) · Life Sciences · doi:10.1016/0024-3205(83)90797-x · Cited by 165
Koh, J. Y., Palmer, E., & Cotman, C. W. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.21.9431 · Cited by 162
Arregui, A., Perry, E. K., Rossor, M., & Tomlinson, B. E. (1982) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1982.tb07930.x · Cited by 156
Lewis, D. A., Campbell, M. J., & Morrison, J. H. (1986) · Journal of Comparative Neurology · doi:10.1002/cne.902480102 · Cited by 161
Neuropeptide Y immunoreactivity is reduced in cerebral cortex in Alzheimer's disease
Beal, M. F., Mazurek, M. F., Chattha, G. K., Svendsen, C. N., Bird, E. D., & Martin, J. B. (1986) · Annals of Neurology · doi:10.1002/ana.410200303 · Cited by 160
Holsboer, F., Spengler, D., & Heuser, I. (1992) · Progress in Brain Research · doi:10.1016/s0079-6123(08)64586-0 · Cited by 159
Neuropeptides in neurological disease
Beal, M. F., & Martin, J. B. (1986) · Annals of Neurology · doi:10.1002/ana.410200502 · Cited by 162
Projections of preBötzinger Complex neurons in adult rats
Tan, W., Pagliardini, S., Yang, P., Janczewski, W. A., & Feldman, J. L. (2010) · Journal of Comparative Neurology · doi:10.1002/cne.22308 · Cited by 150
Fukami, S., Watanabe, K., Iwata, N., Haraoka, J., Lu, B., Gerard, N. P., Gerard, C., Fraser, P., Westaway, D., George-Hyslop, P. S., et al. (2002) · Neuroscience Research · doi:10.1016/s0168-0102(02)00015-9 · Cited by 157
Recent advances in the modeling of Alzheimer’s disease
Sasaguri, H., Hashimoto, S., Watamura, N., Sato, K., Takamura, R., Nagata, K., Tsubuki, S., Ohshima, T., Yoshiki, A., Sato, K., et al. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.807473 · Cited by 157
“Of note, the expression of SRIF in human brain declines with aging and in AD (Davies et al., 1980; Lu et al., 2004) and may causally contribute to AD pathogenesis via reduction of NEP activity/expression.”
BackgroundAlzheimer's disease and senile dementia: Biochemical characteristics and aspects of treatment
Gottfries, C. G. (1985) · Psychopharmacology · doi:10.1007/bf00432208 · Cited by 156
“Studies of somatostatin-like immunoreactivity (SLI) in brain tissue from patients with AD have shown a generalized decrease in many brain regions (Davies et al. 1980; Rossor et al. 1980; Davies and Terry 1981; Davies et al. 1982).”
BackgroundSong, Y.-H., Yoon, J., & Lee, S.-H. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00580-4 · Cited by 145
Takagi, H., Somogyi, P., Somogyi, J., & Smith, A. D. (1983) · Journal of Comparative Neurology · doi:10.1002/cne.902140102 · Cited by 154
Delfs, Jr., & Dichter, M. (1983) · The Journal of Neuroscience · doi:10.1523/jneurosci.03-06-01176.1983 · Cited by 152
“Also, somatostatin levels have been found to be significantly depressed in the brains of patients with senile dementia of the Alzheimer type (Davies et al., 1980).”
BackgroundFriedman, J. I., Adler, D. N., & Davis, K. L. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00232-2 · Cited by 162
Freund, T. F., & Gulyás, A. I. (1991) · Journal of Comparative Neurology · doi:10.1002/cne.903140117 · Cited by 148
Somatostatin and Somatostatin-Containing Neurons in Shaping Neuronal Activity and Plasticity
Liguz-Lecznar, M., Urban-Ciecko, J., & Kossut, M. (2016) · Frontiers in Neural Circuits · doi:10.3389/fncir.2016.00048 · Cited by 139
“Davies et al. (1980) have shown that in AD patients concentration of SOM in cortex and hippocampus was lower than in healthy subjects.”
BackgroundChan‐Palay, V., Lang, W., Allen, Y. S., Haesler, U., & Polak, J. M. (1985) · Journal of Comparative Neurology · doi:10.1002/cne.902380404 · Cited by 146
Flynn, D. D., Weinstein, D. A., & Mash, D. C. (1991) · Annals of Neurology · doi:10.1002/ana.410290305 · Cited by 146
Changes in Blood Glucose and Insulin Secretion in Patients with Senile Dementia of Alzheimer Type
Bucht, G., Adolfsson, R., Lithner, F., & Winblad, B. (1983) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1983.tb03756.x · Cited by 140
Distribution of somatostatin receptors in the human brain: An autoradiographic study
Reubi, J. C., Cortés, R., Maurer, R., Probst, A., & Palacios, J. M. (1986) · Neuroscience · doi:10.1016/0306-4522(86)90158-2 · Cited by 153
Somatostatin receptors: Distribution in rat central nervous system and human frontal cortex
Uhl, G. R., Tran, V. T., Snyder, S. H., & Martin, J. B. (1985) · The Journal of Comparative Neurology · doi:10.1002/cne.902400306 · Cited by 150
Crystal, H. A., & Davies, P. (1982) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1982.tb06665.x · Cited by 142
Self-citationMolecular and cellular mechanisms of selective vulnerability in neurodegenerative diseases
Kampmann, M. (2024) · Nature reviews. Neuroscience · doi:10.1038/s41583-024-00806-0 · Cited by 173
“Soma-tostatin (SST)-expressing interneurons have also been implicated in AD on the basis of a decrease in SST levels in people with AD 20 and SST immunoreactivity in neuritic plaques 21 .”
Neuropeptide coexistence in human cortical neurones
Vincent, S. R., Johansson, O., Hökfelt, T. G. M., Meyerson, B., Sachs, C., Elde, R. P., Terenius, L. Y., & KIMMEL, J. R. (1982) · Nature · doi:10.1038/298065a0 · Cited by 142
A postmortem study of amino acid neurotransmitters in Alzheimer's disease
Ellison, D. W., Beal, M. F., Mazurek, M. F., Bird, E. D., & Martin, J. B. (1986) · Annals of Neurology · doi:10.1002/ana.410200510 · Cited by 139
Evidence for Cholinergic Neurites in Senile Plaques
Kitt, C. A., Price, D. L., Struble, R. G., Cork, L. C., Wainer, B. H., Becher, M. W., & Mobley, W. C. (1984) · Science · doi:10.1126/science.6505701 · Cited by 138
Epelbaum, J., Tapia‐Arancibia, L., Kordon, C., & Enjalbert, A. (1982) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1982.tb06627.x · Cited by 139
Peptidergic transmission: From morphological correlates to functional implications
Zupanc, G. K. H. (1996) · Micron · doi:10.1016/0968-4328(95)00028-3 · Cited by 150
Dawbarn, D., Hunt, S. P., & Emson, P. C. (1984) · Brain Research · doi:10.1016/0006-8993(84)90526-2 · Cited by 136
Blood-brain barrier integrity in the pathogenesis of Alzheimer’s disease
Huang, Z., Wong, L.-W., Su, Y., Huang, X., Wang, N., Chen, H., & Yi, C. (2020) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2020.100857 · Cited by 126
Transgenic Mouse Models of Alzheimer’s Disease: An Integrative Analysis
Sanchez-Varo, R., Mejias-Ortega, M., Fernandez-Valenzuela, J. J., Nuñez-Diaz, C., Caceres-Palomo, L., Vegas-Gomez, L., Sanchez-Mejias, E., Trujillo-Estrada, L., Garcia-Leon, J. A., Moreno-Gonzalez, I., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105404 · Cited by 129
Parkinson's disease and Alzheimer's disease as disorders of the isodendritic core.
Rossor, M. N. (1981) · BMJ · doi:10.1136/bmj.283.6306.1588 · Cited by 132
Neurotransmitters in the cerebral cortex
Jones, E. G. (1986) · Journal of Neurosurgery · doi:10.3171/jns.1986.65.2.0135 · Cited by 131
Hayashi, M., Yamashita, A., & Shimizu, K. (1997) · Brain Research · doi:10.1016/s0006-8993(96)01317-0 · Cited by 133
Molecular Endocrinology and Physiology of the Aging Central Nervous System
Smith, R. G., Betancourt, L., & Sun, Y. (2005) · Endocrine Reviews · doi:10.1210/er.2002-0017 · Cited by 127
Florio, T. (2007) · Frontiers in bioscience · doi:10.2741/2722 · Cited by 128
“In fact, although in Alzheimer disease a reduction of SST content and SST neurons was known by many years (60-62), the alteration of its activity was recently directly associated to the generation of the beta-amyloid, one of the pathogenetic molecules in this kind of dementia (63).”
BackgroundCross, A. J., Crow, T. J., Johnson, J. A., Perry, E. K., Perry, R. H., Blessed, G., & Tomlinson, B. E. (1984) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(84)90029-7 · Cited by 131
Haroutunian, V. H., Mantin, R., Campbell, G. A., Tsuboyama, G. K., & Davis, K. L. (1987) · Brain Research · doi:10.1016/0006-8993(87)90060-6 · Cited by 128
Tong, L. M., Djukic, B., Arnold, C., Gillespie, A. K., Yoon, S. Y., Wang, M. M., Zhang, O., Knoferle, J., Rubenstein, J. L. R., Alvarez-Buylla, A., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.0693-14.2014 · Cited by 123
“AD patients have decreased GABA and somatostatin levels in the brain and CSF (Davies et al., 1980; Bareggi et al., 1982; Zimmer et al., 1984; Hardy et al., 1987; Seidl et al., 2001), and these alterations were more severe in apoE4 carriers (Grouselle et al.”
BackgroundTravis, G. H., & Sutcliffe, J. G. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.5.1696 · Cited by 132
Reduced brain somatostatin in mood disorders: a common pathophysiological substrate and drug target?
Lin, L.-C., & Sibille, E. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00110 · Cited by 116
“…somatostatin immune-reactivity across cortical and subcortical regions is reported in subjects with Alzheimer’s disease, including temporal cortex, frontal cortex, and hippocampus (Davies et al., 1980; Rossor et al., 1980; Davies and Terry, 1981; Candy et al., 1985; Dournaud et al., 1994).”
BackgroundExcitatory-inhibitory imbalance in Alzheimer's disease and therapeutic significance
Vico Varela, E., Etter, G., & Williams, S. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.04.010 · Cited by 118
Chapter 29 Neuropathological changes in Alzheimer disease
Terry, R. D. (1994) · Progress in brain research · doi:10.1016/s0079-6123(08)61964-0 · Cited by 143
Self-citationLeroux, P., Quirion, R., & Pelletier, G. (1985) · Brain Research · doi:10.1016/0006-8993(85)90890-x · Cited by 120
NADPH diaphorase activity in the posterior pituitary: relation to neuronal function
Sagar, S. M., & Ferriero, D. M. (1987) · Brain Research · doi:10.1016/0006-8993(87)90633-0 · Cited by 119
Hilar interneuron vulnerability distinguishes aged rats with memory impairment
Spiegel, A. M., Koh, M. T., Vogt, N. M., Rapp, P. R., & Gallagher, M. (2013) · Journal of Comparative Neurology · doi:10.1002/cne.23367 · Cited by 117
“In the context of age-related cognitive impairment, it is also notable that SOM-expressing interneurons are one of the most vulnerable neuronal populations in AD (Davies et al., 1980; Kumar, 2005).”
BackgroundA disorder of cortical GABAergic innervation in Alzheimer's disease
Hardy, J., Cowburn, R. F., BARTON, A. J. L., Reynolds, G. P., Dodd, P. R., Wester, P. O., O’Carroll, A., Lofdahl, E., & Winblad, B. G. (1987) · Neuroscience Letters · doi:10.1016/0304-3940(87)90016-4 · Cited by 116
Halabisky, B., Shen, F., Huguenard, J. R., & Prince, D. A. (2006) · Journal of Neurophysiology · doi:10.1152/jn.01079.2005 · Cited by 112
Soininen, H. S., Jolkkonen, J., Reinikainen, K. J., Halonen, T., & Riekkinen, P. J. (1984) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(84)90193-x · Cited by 115
Viollet, C., Vaillend, C., Videau, C., Bluet‐Pajot, M., Ungerer, A., L’Héritier, A., Kopp, C., Potier, B., Billard, J., Schaeffer, J. M., et al. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00249.x · Cited by 126
Koliatsos, V. E., Price, D. L., Gouras, G. K., Cayouette, M. H., Burton, L. E., & Winslow, J. W. (1994) · Journal of Comparative Neurology · doi:10.1002/cne.903430206 · Cited by 113
Chan‐Palay, V., Lang, W., Haesler, U., Köhler, C., & Yasargil, G. (1986) · Journal of Comparative Neurology · doi:10.1002/cne.902480307 · Cited by 113
Neurochemical aspects on aging and diseases with cognitive impairment
Gottfries, C. G. (1990) · Journal of Neuroscience Research · doi:10.1002/jnr.490270415 · Cited by 107
“Somatostatin-like immunoreactivity (S) in brain tissue from patients with ADiSDAT has shown a generalized decrease in many brain regions (Davies et al., 1980; Rossor et al., 1980; Davies and Terry, 1981; for a review, see Hardy et a]., 1985; and Cowburn et al., 1989).”
BackgroundBissette, G. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800120034008 · Cited by 110
Banks, W., & Kastin, A. (1983) · The Lancet · doi:10.1016/s0140-6736(83)91273-4 · Cited by 110
Leung, L., Andrews-Zwilling, Y., Yoon, S. Y., Jain, S., Ring, K., Dai, J., Wang, M. M., Tong, L., Walker, D., & Huang, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0053569 · Cited by 109
Basal Forebrain Cholinergic Neurons and Alzheimer’s Disease
Höhmann, C. F., Antuono, P., & Coyle, J. T. (1988) · Springer eBooks · doi:10.1007/978-1-4613-0933-8_2 · Cited by 109
Unsupervised excitation: GABAergic dysfunctions in Alzheimer’s disease
Ambrad Giovannetti, E., & Fuhrmann, M. (2019) · Brain Research · doi:10.1016/j.brainres.2018.11.042 · Cited by 102
Nazarali, A. J., & Reynolds, G. P. (1992) · Cellular and Molecular Neurobiology · doi:10.1007/bf00711237 · Cited by 111
“A significant loss of the neuropeptide somatostatin has been reported, with the greatest deficit occurring in the temporal cortex ( Davies et al., 1980; Ferrier et al., 1983; Rossor et al., 1980).”
BackgroundBeal, M. F., Mazurek, M. F., Svendsen, C. N., Bird, E. D., & Martin, J. B. (1986) · Annals of Neurology · doi:10.1002/ana.410200408 · Cited by 108
Rasool, C. G., Svendsen, C. N., & Selkoe, D. J. (1986) · Annals of Neurology · doi:10.1002/ana.410200407 · Cited by 104
Distribution, Targeting, and Internalization of the sst4Somatostatin Receptor in Rat Brain
Schreff, M., Schulz, S., Händel, M., Keilhoff, G., Braun, H., Pereira, G., Klutzny, M., Schmidt, H., Wolf, G. L., & Höllt, V. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-10-03785.2000 · Cited by 116
“In addition, levels of somatostatin are altered in several human brain dysfunctions, such as senile dementia of the Alzheimer type (Davies et al., 1980; Grouselle et al., 1998) and temporal lobe epilepsy (Robbins et al., 1991).”
Donahue, J. E., Berzin, T. M., Rafii, M. S., Glass, D. J., Yancopoulos, G. D., Fallon, J. R., & Stopa, E. G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.11.6468 · Cited by 100
Bito, H., Mori, M., Sakanaka, C., Takano, T., Honda, Z.-I., Gotoh, Y., Nishida, E., & Shimizu, T. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)99936-9 · Cited by 103
Metabolism of amyloid β peptide and pathogenesis of Alzheimer's disease
Saido, T. C., & Iwata, N. (2006) · Neuroscience Research · doi:10.1016/j.neures.2005.12.015 · Cited by 111
Glorioso, C. A., Sabatini, M., Unger, T. L., Hashimoto, T., Monteggia, L. M., Lewis, D. A., & Mirnics, K. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001835 · Cited by 105
Kumar, U. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.04.001 · Cited by 101
Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type.
Tato, R. E., Frank, A., & Hernanz, A. (1995) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.59.3.280 · Cited by 99
Neurotransmitter and Receptor Deficits in Senile Dementia of the Alzheimer Type
Quirion, R., Martel, J.-C., Robitaille, Y., Etienne, P. E., Wood, P. L., Nair, N. P. V., & Gauthier, S. G. (1986) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100037215 · Cited by 107
Oxidative mechanisms involved in kainate-induced cytotoxicity in cortical neurons
Cheng, Y., & Sun, A. Y. (1994) · Neurochemical Research · doi:10.1007/bf00969006 · Cited by 103
“been related to lathyrism (6,7) and amyotrophic lateral sclerosis (ALS) (8), as well as Alzheimer's disease ( 9 ).”
BackgroundKowall, N. W., Pendlebury, W. W., Kessler, J. B., Perl, D. P., & Beal, M. F. (1989) · Neuroscience · doi:10.1016/0306-4522(89)90060-2 · Cited by 100
Hilar GABAergic Interneuron Activity Controls Spatial Learning and Memory Retrieval
Andrews-Zwilling, Y., Gillespie, A. K., Kravitz, A. V., Nelson, A. B., Devidze, N., Lo, I., Yoon, S. Y., Bien-Ly, N., Ring, K., Zwilling, D., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040555 · Cited by 93
Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex
Gabriel, S. M., Davidson, M. H., Haroutunian, V. H., Powchik, P., Bierer, L. M., Purohit, D. P., Perl, D. P., & Davis, K. L. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(95)00066-6 · Cited by 97
Cloning and expression of a rat somatostatin receptor enriched in brain.
Li, X. J., Forte, M. A., North, R. A., Ross, C. A., & Snyder, S. H. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36609-8 · Cited by 95
Somatostatin, Alzheimer's disease and cognition: An old story coming of age?
Epelbaum, J., Guillou, J., Gastambide, F., Hoyer, D., Duron, E., & Viollet, C. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.07.002 · Cited by 104
Alzheimer's Disease and Down's Syndrome*
Price, D. L., Whitehouse, P. J., Struble, R. G., Coyle, J. T., Clark, A. W., DeLong, M. R., Cork, L. C., & Hedreen, J. C. (1982) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1982.tb26850.x · Cited by 102
Grouselle, D., Winsky-Sommerer, R., David, J. P., Delacourte, A., Dournaud, P., & Epelbaum, J. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00698-3 · Cited by 92
Cerebrospinal Fluid Vasopressin, Oxytocin, sopressin, Oxytoc in Alzheimer's Diseasβ-Endorphin
Raskind, M. A. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800040092013 · Cited by 91
RS 86 in the treatment of alzheimer's disease: Cognitive and biological effects
Hollander, E., Davidson, M., Mohs, R. C., Horvath, T., Davis, B. M., Zemishlany, Z., & Davis, K. L. (1987) · Biological Psychiatry · doi:10.1016/0006-3223(87)90049-7 · Cited by 91
Kowall, N. W., & Mueller, M. (1988) · Neuroscience · doi:10.1016/0306-4522(88)90171-6 · Cited by 92
Neurotransmitters, neuroreceptors and aging
Amenta, F., Zaccheo, D., & Collier, W. L. (1991) · Mechanisms of Ageing and Development · doi:10.1016/0047-6374(91)90059-9 · Cited by 90
Selective messenger RNA reduction in Alzheimer's disease
McLachlan, D. R. C., Lukiw, W. J., Wong, L. J., Bergeron, C., & Bech‐Hansen, N. T. (1988) · Molecular Brain Research · doi:10.1016/0169-328x(88)90048-4 · Cited by 103
Catecholamines and Cognitive Decline in Aged Nonhuman Primates
Arnsten, A. F. T., & Goldman, P. S. (1985) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1985.tb37592.x · Cited by 96
Lawlor, B. A. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810060064010 · Cited by 89
Somatostatin and Alzheimer's disease
Burgos‐Ramos, E., Hervás‐Aguilar, A., Aguado‐Llera, D., Puebla‐Jiménez, L., Hernández‐Pinto, A. M., Barrios, V., & Arilla, E. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.01.014 · Cited by 99
Somatostatin-like immunoreactivity within neuritic plaques
Armstrong, D. M., LeRoy, S., Shields, D., & Terry, R. D. (1985) · Brain Research · doi:10.1016/0006-8993(85)90249-5 · Cited by 88
Self-citationEvidence for the existence of serotonin type-2 receptors on cholinergic terminals in rat cortex
Quirion, R., Richard, J., & Dam, T. V. (1985) · Brain Research · doi:10.1016/0006-8993(85)91590-2 · Cited by 88
Fuhrer, T. E., Palpagama, T. H., Waldvogel, H. J., Synek, B. J., Turner, C. P., Faull, R. L. M., & Kwakowsky, A. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.03.041 · Cited by 86
“Somatostatin-positive neurons within the cortex, which are co-localized with GABA, are reduced in AD, providing support for the contribution of GABAergic abnormalities (Davies et al., 1980).”
Dementia and Parkinson's Disease
Gibb, W. R. G. (1989) · The British Journal of Psychiatry · doi:10.1192/bjp.154.5.596 · Cited by 91
Kamal, Z., Ullah, F., Ayaz, M., Sadiq, A., Ahmad, S., Zeb, A., Hussain, A., & Imran, M. (2015) · Biological Research · doi:10.1186/s40659-015-0011-1 · Cited by 86
“AD is also associated with loss of synapses, synaptic dysfunctions, mitochondrial abnormalities and inflammatory stress [5] that may lead to multi neurotransmitters deficiency like, acetylcholine [6], noradrenalin [7], serotonin [8] and somatostatin [9].”
BackgroundSomatostatinergic systems: an update on brain functions in normal and pathological aging
Martel, G., Dutar, P., Epelbaum, J., & Viollet, C. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00154 · Cited by 85
“Indeed, since the early 1980s, it is known that SRIF levels in cortex and hippocampus are decreased in AD patients (Davies et al., 1980).”
BackgroundCultured GABA-immunoreactive neurons are resistant to toxicity induced by β-amyloid
Pike, C. J., & Cotman, C. W. (1993) · Neuroscience · doi:10.1016/0306-4522(93)90331-9 · Cited by 90
Drugs to Treat Age‐Related Neurodegenerative Problems The Final Frontier of Medical Science?
Bartus, R. T. (1990) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1990.tb01430.x · Cited by 86
Krieger, D. T., & Martin, J. B. (1981) · New England Journal of Medicine · doi:10.1056/nejm198104163041605 · Cited by 86
Tong, L. M., Fong, H., & Huang, Y. (2015) · Experimental & Molecular Medicine · doi:10.1038/emm.2014.124 · Cited by 83
Bürger, C., López, M. C., Feller, J. A., Baker, H. V., Muzyczka, N., & Mandel, R. J. (2006) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2006.05.003 · Cited by 91
Metadata
- Authors
- Davies, P., Katzman, R., & Terry, R. D.
- Affiliations
- Albert Einstein College of Medicine (US)
- Venue
- Nature
- Published
- 1980-11
- Volume
- 288
- Issue
- 5788
- Pages
- 279-280
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2034969383
- Cited by
- 882
- References
- 9
- Citations by year
- 2026: 6 · 2025: 12 · 2024: 20 · 2023: 18 · 2022: 11 · 2021: 11 · 2020: 19 · 2019: 8 · 2018: 9 · 2017: 5 · 2016: 7 · 2015: 7 · 2014: 7 · 2013: 9 · 2012: 8
- FWCI
- 25.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- Alzheimer's disease, senile dementia of the Alzheimer type, somatostatin, somatostatin-like immunoreactivity, cerebral cortex, neuropeptides, peptidergic neurons, neurotransmitter systems, cholinergic neurons, neurofibrillary tangles, neuritic plaques
- MeSH terms
- Aged, Alzheimer Disease, Cerebral Cortex, Choline O-Acetyltransferase, Dementia, Humans, Middle Aged, Radioimmunoassay, Somatostatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.